Trial Profile
A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Nivolumab (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer
- Focus Therapeutic Use
- 19 Oct 2017 New trial record